Everolimus is a type of mTOR inhibitor, a hydroxyethyl derivative of sirolimus, which binds to an intracellular protein (FKBP-12) to form an inhibitory complex with the mTOR complex (mTORC1), thereby inhibiting the activity of mTOR kinase, and also reduces the expression of vascular endothelial growth factor (VEGF) then inhibits tumor angiogenesis [89,90]. The gene discussed is FKBP1A; the disease is neoplasm.